Elanix Teams With Dermacon To Develop New Wound-Care Devices
Executive Summary
Swiss start-up Elanix Biotechnologies has signed an agreement with German firm Dermacon GmbH to develop progenitor cell medical devices for wound healing. Elanix has set its sights for a 2020 European launch of the devices.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Abbott Surprises Analysts With CE Mark For Freestyle Libre 3
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.